APA (7th ed.) Citation

Huh, W. K., Sill, M. W., Darcy, K. M., Elias, K. M., Hoffman, J. S., Boggess, J. F., . . . Birrer, M. J. (2010). Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecologic oncology, 117(2), 248-254. https://doi.org/10.1016/j.ygyno.2010.01.002

Chicago Style (17th ed.) Citation

Huh, Warner K., et al. "Efficacy and Safety of Imatinib Mesylate (Gleevec®) and Immunohistochemical Expression of C-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in Women with Recurrent or Persistent Carcinosarcomas of the Uterus." Gynecologic Oncology 117, no. 2 (2010): 248-254. https://doi.org/10.1016/j.ygyno.2010.01.002.

MLA (9th ed.) Citation

Huh, Warner K., et al. "Efficacy and Safety of Imatinib Mesylate (Gleevec®) and Immunohistochemical Expression of C-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in Women with Recurrent or Persistent Carcinosarcomas of the Uterus." Gynecologic Oncology, vol. 117, no. 2, 2010, pp. 248-254, https://doi.org/10.1016/j.ygyno.2010.01.002.